← Leaderboards
Andrey Komissarov
University Of Texas Hlth Ctr At Tyler
$3,479,251
Attributed
$8,504,079
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,504,079 · 5
By mechanism
R01$6,255,148 · 2
R33$881,243 · 1
P50$868,103 · 1
R61$499,585 · 1
Top collaborators
- Steven Idell14 shared
- Galina Florova12 shared
- Melvin E Klegerman4 shared
- Alexander B Sigalov1 shared
Most similar at University Of Texas Hlth Ctr At Tyler
Same institution · by research overlap
- Steven Idell$6,820,677
- Galina Florova$1,545,576
- Torry Alle Tucker$3,028,800
- Guoqing Qian$1,204,269
- Sreerama Shetty$8,298,919
Others in their field
Top investigators on “Injury”
- Polly Chang · Sri International$119,352,977
- Marco Pahor · Wake Forest University Health Sciences$82,312,292
- Kerry J Kelly · New York City Fire Department$81,924,266
- Asrar B. Malik · University Of Illinois At Chicago$81,164,529
- Peter Scott Heeger · Case Western Reserve University$76,259,223
- Jacqueline Moline · Icahn School Of Medicine At Mount Sinai$75,762,106
Research focus
InjuryPleuralEmpyemaOryctolagus CuniculusLiquid SubstanceDoseThrombolytic TherapyFibrinIncidenceInnovationHemorrhagePlasminogen Activator Inhibitor 1UltrasonographyImproved OutcomeComplicationStreptococcus PneumoniaeLungMortalityTherapy OutcomeFibrinolysisAcuteMolecularPathogenesisSampling
Grant awards (19)
Concurrent targeting of inflammation and the inhibition of the fibrinolytic system to increase the efficacy of empyema treatment$499,585
R61 · FY2025 · HL · contact PI
Enhanced Delivery of Thrombolytic Carriers for Empyema$609,709
R01 · FY2024 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$524,404
R01 · FY2024 · HL · contact PI
Enhanced Delivery of Thrombolytic Carriers for Empyema$622,151
R01 · FY2023 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$535,106
R01 · FY2023 · HL · contact PI
Enhanced Delivery of Thrombolytic Carriers for Empyema$622,151
R01 · FY2022 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$535,336
R01 · FY2022 · HL · contact PI
Enhanced Delivery of Thrombolytic Carriers for Empyema$645,651
R01 · FY2021 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$547,086
R01 · FY2021 · HL · contact PI
Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic Interventions$440,243
R33 · FY2021 · HL
Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic Interventions$441,000
R33 · FY2020 · HL
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$352,311
R01 · FY2020 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$416,339
R01 · FY2019 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$448,525
R01 · FY2018 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$364,557
R01 · FY2017 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$15,911
R01 · FY2017 · HL · contact PI
Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema$15,911
R01 · FY2017 · HL · contact PI
PAI-1 Targeted Intrapleural Fibronolytic Therapy$424,780
P50 · FY2012 · HL
PAI-1 Targeted Intrapleural Fibronolytic Therapy$443,323
P50 · FY2011 · HL